SEC filings and other documents

Robust pipeline progress, strong cash position, and milestone collaboration payment highlight Q1 2026.

Clinical progress and a key collaboration support robust pipeline and financial position.

JANX007 achieves durable efficacy and safety in early line prostate cancer with Q2W dosing.

Strong cash reserves and pipeline progress support ongoing clinical development.

Strong cash position supports advancing immunotherapy pipeline amid rising R&D expenses.

Innovative bispecifics pipeline advances in oncology and autoimmune disease with strong data and funding.

JANX007 and JANX008 clinical progress continues as cash reserves top $1 billion.

Positive Phase 1 data and a $1.03B cash position support Janux's advancing oncology pipeline.

JANX007 delivers robust, durable responses and strong safety in advanced prostate cancer.

Q3 net loss widened to $28.1M as cash reserves grew to $658M, funding key clinical trials.

Cash position surged and net loss narrowed as clinical pipeline advanced and Merck milestone hit.